MedTrace Logo

MYeloma Resistance And Clonal Evolution

NCT03807128 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1400

Last updated 2025-07-14

No results posted yet for this study

Summary

Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.

Conditions

Interventions

OTHER

Prélèvement sanguin (2*4mL) ou médullaire (2mL)

Additional blood (2\*4mL) or bone marrow (2mL) sample depending on clinical presentation of disease

OTHER

Data collection through questionnaires

Collection of quality of life and occupational exposure data via questionnaires

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Cyrille TOUZEAU, PU · Nantes University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-11
Primary Completion
2034-02-11
Completion
2049-02-11

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03807128 on ClinicalTrials.gov